Abstract: The invention is directed to a synergistic radiation protective pharmaceutical composition comprising 50 to 350 parts by weight of aminoalkyl-thiol-derivatives of the general formula II ##STR1## wherein R.sup.3 stands for hydrogen, or carboxamidinoR.sup.4 stands for hydrogen or carboxy,B represents hydrogen or carboxamidino with the restriction that at least two of R.sup.3, R.sup.4 and B stand for hydrogen--or a pharmaceutically acceptable acid addition salt thereof, 0.2 to 2 parts by weight of .omega.-acylamino-alkane-derivative of the general formula ##STR2## wherein R.sup.1 stands for hydrogen, C.sub.1-4 alkanoyl, aroyl or aryl-(C.sub.1-4)-alkoxy-carbonyl,R.sup.2 stands for hydrogen, or carboxy optionally esterified by C.sub.1-4 alkoxy or aryl-(C.sub.1-4)alkoxy,A stands for --SO.sub.2 OH or --O--PO(OH).sub.2,n stands for 1, 2 or 3 andm stands for 2, 3 or 4--or a pharmaceutically acceptable salt thereof,and pharmaceutically acceptable carriers, diluents and/or solvents, and/or other formulating excipients.

Abstract: A process for preparing gamma-L-glutamyl-taurine, which has been found to be effective therapeutically through the control of vitamin A metabolism, which comprises reacting carbobenzyloxy-L-glutaminic acid-.alpha.-benzyl ester with triethylamine and isobutylchloroformate and then treating the reaction mixture with cystamine dihydrochloride to recover N,N'-bis-(N-carbobenzyloxy-gamma-[.alpha.-benzyl]-L-glutamyl)-cystamine. The latter is reacted with hydrogen peroxide in glacial acetic acid to produce carbobenzyloxy-gamma-(.alpha.-benzyl)-L-glutamyl taurine. The latter compound is treated with hydrogen bromide in glacial acetic acid to recover the gamma-(.alpha.-benzyl)-L-glutamyl taurine and this compound is treated with potassium hydroxide solution to yield the gamma-L-glutamyl taurine.

Abstract: A deproteinized, defatted aqueous extract of the parathyroid gland insoluble in benzene, chloroform and carbon tetrachloride is found to be L-gamma-glutamyl-taurine which has vitamin-A type activity and is generally effective for the treatment of a wide range of mammalian disorders which are directly or indirectly connected with pathological alterations of the aerobiospherical genetical adaptational system (AGAS).

Abstract: The invention relates to novel .omega.-aminocarboxylic acid amides having the formula (I) ##STR1## wherein A is --SO.sub.2 OH or --OPO(OH).sub.2,R.sup.1 is hydrogen, an acyl group, such as benzoyl, arylsulfonyl, alkoxycarbonyl, cycloalkoxycarbonyl or aralkoxycarbonyl group or an aralkoxycarbonyl group having a halogen, alkoxy, nitro, phenylazo or alkoxyphenylazo substituent, alkyl-substituted aryloxycarbonyl or carbonyl,R.sup.2 is hydrogen or a carbonyl group, with the proviso that when R.sup.1 and R.sup.2 each stand for carbonyl, the two carbonyl groups form a ring through an intervening o-phenylene, alkylene or vinylene group when A is --SO.sub.2 OH and R.sup.1 is an acyl group such as benzoyl, aryl sulfonyl, alkoxy-carbonyl, cycloalkoxycarbonyl or aryloxycarbonyl group or an aralkoxy carbonyl group having a halogen, alkoxy, nitro, phenylozo or alkoxyphenylazo substituent or an alkyl-substituted aryloxycarbonyl group or carbonyl group,R.sup.2 is hydrogen or a carbonyl group, with the proviso that when R.

Abstract: An animal feed containing 0.00002 to 0.1% by weight of:2-methyl-7-methoxy-4'-nitroisoflavone,7-[hydroxyethoxy]-2-methylisoflavone,7-carbethoxy-2-methylisoflavone,7-ethoxyisoflavone,7-n-benzyloxy-2-methylisoflavone,7-p-nitrobenzyloxyisoflavone,7-p-nitrobenzyloxy-2-methylisoflavone,7-p-chlorobenzyloxyisoflavone,7-cetyloxy-2-methylisoflavone,7-(2-octyloxy)-isoflavone,7-benzyloxy-3',4'-dimethoxyisoflavone, and7-hexadecyloxyisoflavoneAs a weight-gain promoting anabolic ingredient.

Abstract: Nonestrogenic 5-methyl-alkoxy-isoflavone, namely, 5-methyl-7-methoxy-isoflavone, 5-methyl-7-ethoxy-isoflavone, 5-methyl-7-isopropoxy-isoflavone, and 5-methyl-7-(2-hydroxy-ethoxy)-isoflavone are useful as weight-gain promoters in feeds from which the 7-methoxy and 7-ethoxy isoflavones have been excluded because of estrogenic effects. They are more effective than 7-isopropoxy-isoflavone as well.

Abstract: Gamma-L-glutamyl cholamine phosphate and beta-L-aspartyl cholamine phosphates are disclosed, the compounds having blood-sugar-level lowering and serum vitamin A increasing effect.

Abstract: Compounds of the formula: ##STR1## or pharmaceutically acceptable salts thereof, wherein: A is --OPO(OH).sub.2 ;R.sup.1 is hydrogen, acetyl or benzoyl;R.sup.2 is hydrogen; andn is 2 or 3 with the ability to decrease blood sugar are disclosed.

Abstract: A deproteinized, defatted aqueous extract of the parathyroid gland insoluble in benzene, chloroform and carbontetrachloride. The composition has vitamin-A type activity and is generally effective for the treatment of irradiation injury.

Abstract: A method of anabolic treatment in humans comprises administering a compound of the following formula: ##SPC1##Wherein R is halosubstituted, nitrosubstituted, or unsubstituted benzyl, R.sup.2 is hydrogen, methyl or carboxy, and R.sup.3 and R.sup.4 are hydrogen, methoxy or nitro. Pharmaceutical compositions are also disclosed.